Because tocilizumab prevents the binding of IL-6 to IL-6 receptors, thereby increasing the serum concentration of free IL-6 (25), it is not surprising that the serum IL-6 concentration in the severe COVID-19 patients was increased after these patients were treated with tocilizumab. Here, IL6 is linked to COVID-19.